PMLive5h
Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use
Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the US Food and Drug ...
BioPharma Dive3d
FDA broadens use of Novartis’ radiopharma drug Pluvicto
Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...
Fierce Pharma3d
Novartis' prostate cancer drug Pluvicto wins key FDA nod toward $5B-plus sales target
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
Renal & Urology News1d
FDA Expands Approval of Pluvicto in PSMA-Positive Metastatic CRPC
The FDA expanded the approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and are considered appropriate to ...
STAT1d
Emotional whiplash for PTC Therapeutics
Pluvicto, Novartis’ blockbuster radiopharmaceutical for prostate cancer, has been greenlighted by the FDA for use earlier in ...
Medscape1d
FDA Approves Pluvicto for Earlier Use in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor pathway inhibitor.
Explore more
The Pharma Letter1d
Novartis’ Pluvicto gets FDA green light for mCRPC
Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...
ASP Isotopes Inc. Completes Commissioning of First Quantum Enrichment Laser System and Starts Production of Commercial Samples of Ytterbium-176
Ytterbium-176 is a critical material used in the production of radioisotopes for oncology treatments, including Novartis’ Pluvicto. - The ...
Healio3d
FDA expands Pluvicto indication for earlier use in patients with prostate cancer
The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane ...
FDA approves Novartis radioligand therapy Pluvicto for earlier use in mCRPC
Novartis (NVS) announced that the Food and Drug Administration approved Pluvicto for patients with prostate-specific membrane antigen-positive ...
CURE3d
FDA Expands Pluvicto Indication in Prostate Cancer Subset
FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with ...
Cancer Therapy Advisor1d
FDA Expands Approval of Pluvicto in PSMA-Positive mCRPC
The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.